Related references
Note: Only part of the references are listed.An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease
Jixin Zhong et al.
ATHEROSCLEROSIS (2013)
GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE(-/-) Mice
Naim Panjwani et al.
ENDOCRINOLOGY (2013)
Anagliptin, a DPP-4 Inhibitor, Suppresses Proliferation of Vascular Smooth Muscles and Monocyte Inflammatory Reaction and Attenuates Atherosclerosis in Male apo E-Deficient Mice
Nasib Ervinna et al.
ENDOCRINOLOGY (2013)
Exendin-4 inhibits iNOS expression at the protein level in LPS-stimulated Raw264.7 macrophage by the activation of cAMP/PKA pathway
Seo-Yoon Chang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2013)
Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation
Daisuke Shiraishi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice
Y. Takeda et al.
DIABETOLOGIA (2012)
Cardiovascular Biology of the Incretin System
John R. Ussher et al.
ENDOCRINE REVIEWS (2012)
A Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improves Endothelial Function and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E-Deficient Mice
Junichi Matsubara et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice
Michishige Terasaki et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2012)
Glucose-Dependent Insulinotropic Polypeptide Prevents the Progression of Macrophage-Driven Atherosclerosis in Diabetic Apolipoprotein E-Null Mice
Yukinori Nogi et al.
PLOS ONE (2012)
Potential cardiovascular effects of incretin-based therapies
Carolyn F. Deacon et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2012)
Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis
Zubair Shah et al.
CIRCULATION (2011)
Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
M. Nagashima et al.
DIABETOLOGIA (2011)
DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E-Deficient Mice
Nga N. Ta et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2011)
Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
Gian Paolo Fadini et al.
VASCULAR PHARMACOLOGY (2011)
Preventive Effects of Heregulin-β1 on Macrophage Foam Cell Formation and Atherosclerosis
Gang Xu et al.
CIRCULATION RESEARCH (2009)
Impact of salusin-α and -β on human macrophage foam cell formation and coronary atherosclerosis
Takuya Watanabe et al.
CIRCULATION (2008)
Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets
Jie Zhou et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2007)
Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: Nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1
Nicola A. Duffy et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Beta-cell expression of a dominant-negative HNF-1α compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice
B Ahrén et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2005)
Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors
T Hansotia et al.
DIABETES (2004)
Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors
F Preitner et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats
FC Lynn et al.
DIABETES (2001)
Share Paper
